leisure time -WSS

leisure time

author：knowledge 2025-08-04 03:40:17 - browse：4

Illustration of a road with a chasm in the middle, indicating the end of a deal or a problem with a deal — Adobe

A deal is never really done until it’s done.

On Tuesday, two different proposed insurance plan acquisitions on different sides of the country called it quits — one of them for the second time.

California-based Medicare Advantage insurer SCAN Group has been trying to buy CareOregon, an insurer offering coverage to half a million people in Oregon’s state health plan, since January 2023. National insurer Elevance has also been trying to buy Blue Cross and Blue Shield of Louisiana since last January. The on-again, off-again purchase was paused in September 2023 because of state regulators’ concerns, but was resubmitted with a slightly different plan in December.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： How to save health care price transparency rules

explore

WSS

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

First U.S. drug developed to treat liver disease MASH is approved

Why depression after traumatic brain injury is distinct

WuXi out of biotech trade group, U.S. and China relations to blame

How to save health care price transparency rules

RaDonda Vaught links Vanderbilt hospital issues to patient death

hotspot

leisure time

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Covid hospitalizations on the rise, Humana says

Psychedelics group wrestles with new pharma identity

Weighted lottery helped low

Guidelines to prevent youth baseball injuries need more muscle

First U.S. drug developed to treat liver disease MASH is approved

Heart attack and stroke risk calculators need revising

Ebola: Gilead Sciences antiviral shows promise as new treatment

Jerome Adams on the need for new antivirals for Covid

WuXi out of biotech trade group, U.S. and China relations to blame

knowledge

How generative AI is inspiring dreams of a health data revolution

FDA advisers back CAR

Why depression after traumatic brain injury is distinct

How to fix cancer clinical trials' diversity problem

How many hemophilia patients actually want gene therapy?

Ebola: Gilead Sciences antiviral shows promise as new treatment

knowledge

explore

leisure time

explore